Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials

Tumor Biology(2014)10.1007/s13277-014-1635-4Source: DataRank Database

The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials is a research paper published in Tumor Biology (2014). On theSindex it has a DataRank of 1.0. It has been cited 7 times, with 6 citing works in its 1-hop citation network.

N/A

1.0DataRank · unranked

Scored on demand from live citation data

7 citations · 6 citing works in its network

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Impact (FWCI 0.22)OA: closedTopics (25)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (0/2)

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 31%Citation Network 69%

Base Score Contribution

0.312

From this paper's citation signal

Citation Network Contribution

0.692

From 6 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 6 citers.

Comment on Wang et al.: The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials
Tumor Biology20142 citations2 referencesContributes 0.549
The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials
Tumor Biology201415 citations31 referencesContributes 0.089
Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)
BMC Cancer20217 citations36 referencesContributes 0.058
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015
Breast Care201512 citations56 referencesContributes 0.046
Comparative Effectiveness of Taxane‐Containing Regimens for Treatment of HER2‐Negative Metastatic Breast Cancer: A Network Meta‐analysis
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy20194 citations43 referencesContributes 0.037

Authors (6)

Chun Huang ORCID,Man Li ORCID,Yanjun Gu,Yanfen Cui ORCID,Yan Li ORCID

Live enrichment

PubMed:24570182 OpenAlex:https://openalex.org/W2077649377

FWCI

0.22

Citation Percentile

0.3%

Citation Trend

2014

2015

2016

2019

2021

closedLicense: http://www.springer.com/tdm

publisherhttp://link.springer.com/content/pdf/10.1007/s13277-014-1635-4.pdf

publisherhttp://link.springer.com/article/10.1007/s13277-014-1635-4/fulltext.html

publisherhttp://link.springer.com/content/pdf/10.1007/s13277-014-1635-4

journalhttps://doi.org/10.1007/s13277-014-1635-4

repositoryhttps://pubmed.ncbi.nlm.nih.gov/24570182

Fields of Study

Cancer Treatment and PharmacologyHER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies

MeSH Terms

BevacizumabAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleHumansRandomized Controlled Trials as TopicPaclitaxelReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, Humanized

Keywords

BevacizumabMedicineMetastatic breast cancerOncologyPaclitaxelInternal medicineBreast cancerChemotherapyMeta-analysisProgression-free survivalRandomized controlled trialCancer

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)

10.6084/m9.figshare.14936151.v1figshare

10.6084/m9.figshare.14936151figshare